Bank of New York Mellon’s Gyre Therapeutics GYRE Stock Holding History

Bank of New York Mellon’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$414K	Buy	62,750 +19,606	+45%	+$134K	﹤0.01%	3843
2026 Q1	$301K	Buy	43,144 +1,941	+5%	+$15.1K	﹤0.01%	3854
2025 Q4	$291K	Buy	41,203 +16,805	+69%	+$130K	﹤0.01%	3878
2025 Q3	$182K	Buy	24,398 +409	+2%	+$3.11K	﹤0.01%	4042
2025 Q2	$176K	Buy	23,989 +7,497	+45%	+$65.4K	﹤0.01%	4020
2025 Q1	$127K	Buy	16,492 +2,596	+19%	+$28.5K	﹤0.01%	3969
2024 Q4	$168K	Buy	13,896 +1,389	+11%	+$17.8K	﹤0.01%	3984
2024 Q3	$157K	Sell	12,507 -5,759	-32%	-$74.3K	﹤0.01%	3954
2024 Q2	$218K	Buy	+18,266	New	+$251K	﹤0.01%	3921
2023 Q2	–	Sell	-13,376	Closed	-$41.5K	–	4422
2023 Q1	$41.5K	Sell	13,376 -13,376	-50%	-$50.8K	﹤0.01%	4222
2022 Q4	$106K	Sell	26,752 -201	-0.7%	-$820	﹤0.01%	4104
2022 Q3	$102K	Hold	26,953	–	–	﹤0.01%	4192
2022 Q2	$360K	Sell	26,953 -1,955	-7%	-$13K	﹤0.01%	3783
2022 Q1	$143K	Buy	28,908 +18,867	+188%	+$93.5K	﹤0.01%	4333
2021 Q4	$69K	Hold	10,041	–	–	﹤0.01%	4456
2021 Q3	$309K	Hold	10,041	–	–	﹤0.01%	4025
2021 Q2	$326K	Sell	10,041 -8,153	-45%	-$280K	﹤0.01%	3937
2021 Q1	$688K	Buy	18,194 +7,504	+70%	+$343K	﹤0.01%	3525
2020 Q4	$506K	Buy	10,690 +226	+2%	+$9.79K	﹤0.01%	3612
2020 Q3	$337K	Buy	10,464 +958	+10%	+$37.5K	﹤0.01%	3671
2020 Q2	$419K	Buy	9,506 +6,053	+175%	+$284K	﹤0.01%	3562
2020 Q1	$113K	Sell	3,453 -32	-0.9%	-$1.47K	﹤0.01%	3841
2019 Q4	$178K	Hold	3,485	–	–	﹤0.01%	3945
2019 Q3	$128K	Hold	3,485	–	–	﹤0.01%	3989
2019 Q2	$192K	Sell	3,485 -4,266	-55%	-$267K	﹤0.01%	3934
2019 Q1	$472K	Sell	7,751 -335	-4%	-$21.5K	﹤0.01%	3584
2018 Q4	$478K	Sell	8,086 -1,742	-18%	-$128K	﹤0.01%	3511
2018 Q3	$794K	Buy	9,828 +2,120	+28%	+$168K	﹤0.01%	3400
2018 Q2	$675K	Buy	7,708 +3,577	+87%	+$627K	﹤0.01%	3468
2018 Q1	$799K	Buy	4,131 +1,198	+41%	+$223K	﹤0.01%	3335
2017 Q4	$300K	Sell	2,933 -9	-0.3%	-$459	﹤0.01%	3798
2017 Q3	$111K	Sell	2,942 -110	-4%	-$3.3K	﹤0.01%	3994
2017 Q2	$107K	Buy	+3,052	New	+$110K	﹤0.01%	4014
2017 Q1	–	Sell	-154	Closed	-$11K	–	4297
2016 Q4	$11K	Sell	154 -2	-1%	-$180	﹤0.01%	4242
2016 Q3	$21K	Sell	156 -34	-18%	-$5.13K	﹤0.01%	4214
2016 Q2	$32K	Buy	190 +26	+16%	+$4.43K	﹤0.01%	4237
2016 Q1	$31K	Hold	164	–	–	﹤0.01%	4137
2015 Q4	$58K	Sell	164 -1	-0.6%	-$393	﹤0.01%	4159
2015 Q3	$86K	Buy	165 +1	+0.6%	+$1.52K	﹤0.01%	4143
2015 Q2	$362K	Buy	164 +6	+4%	+$12K	﹤0.01%	3730
2015 Q1	$369K	Hold	158	–	–	﹤0.01%	3720
2014 Q4	$327K	Hold	158	–	–	﹤0.01%	3755
2014 Q3	$314K	Hold	158	–	–	﹤0.01%	3772
2014 Q2	$560K	Sell	158 -141	-47%	-$460K	﹤0.01%	3573
2014 Q1	$1.12M	Sell	299 -3	-1%	-$11.1K	﹤0.01%	3215
2013 Q4	$988K	Buy	302 +30	+11%	+$118K	﹤0.01%	3316
2013 Q3	$1.14M	Buy	272 +71	+35%	+$286K	﹤0.01%	3168
2013 Q2	$675K	Buy	+201	New	+$765K	﹤0.01%	3381

Other funds holding GYRE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

Bank of New York Mellon's GYRE Position: Q2 2026 in Review

Bank of New York Mellon increased its Gyre Therapeutics (GYRE) stake by 45% in Q2 2026, buying an estimated $134K and bringing the position to 62,750 shares worth $414K. The position accounts for ﹤0.01% of the portfolio, ranked #3843.

Bank of New York Mellon first reported a position in GYRE in Q2 2013 and has held it in 48 quarters since. The position peaked at $1.14M in Q3 2013. 29 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

Bank of New York Mellon held 62,750 shares of Gyre Therapeutics worth $414K as of Q2 2026.
Bank of New York Mellon bought 19,606 Gyre Therapeutics shares in Q2 2026, an estimated $134K.
Gyre Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3843 holding.
Bank of New York Mellon first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 48 quarters since.
Bank of New York Mellon's Gyre Therapeutics position peaked at $1.14M in Q3 2013.
29 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.